Gene therapy tackles Alzheimer's in High-Risk patients
Disease control
Completed
This study tested a gene therapy called LX1001 in 15 people with a specific genetic form of Alzheimer's disease (APOE4 homozygotes). The goal was to check if the treatment is safe and to look for side effects. Participants had mild cognitive impairment or mild to moderate dementi…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 17, 2026 07:05 UTC